IMNM
NASDAQ HealthcareImmunome, Inc. - Common Stock
Biotechnology
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
๐ Market Data
| Price | $22.73 |
|---|---|
| Volume | 949,710 |
| Market Cap | 2.57B |
| Beta | 2.140 |
| RSI (14-Day) | 51.0 |
| 200-Day MA | $17.63 |
| 50-Day MA | $21.89 |
| 52-Week High | $27.65 |
| 52-Week Low | $7.15 |
| Forward P/E | -10.75 |
| Price / Book | 4.05 |
๐ฏ Investment Strategy Scores
IMNM scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (94/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (4/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find IMNM in your text
Paste any article, transcript, or post โ the tool will extract IMNM and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.